Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 23

1.

Biased antagonism of CXCR4 avoids antagonist tolerance.

Hitchinson B, Eby JM, Gao X, Guite-Vinet F, Ziarek JJ, Abdelkarim H, Lee Y, Okamoto Y, Shikano S, Majetschak M, Heveker N, Volkman BF, Tarasova NI, Gaponenko V.

Sci Signal. 2018 Oct 16;11(552). pii: eaat2214. doi: 10.1126/scisignal.aat2214.

2.

Bicelle size modulates the rate of bacteriorhodopsin folding.

Gruenhagen TC, Ziarek JJ, Schlebach JP.

Protein Sci. 2018 Jun;27(6):1109-1112. doi: 10.1002/pro.3414. Epub 2018 Apr 25.

3.

15N detection harnesses the slow relaxation property of nitrogen: Delivering enhanced resolution for intrinsically disordered proteins.

Chhabra S, Fischer P, Takeuchi K, Dubey A, Ziarek JJ, Boeszoermenyi A, Mathieu D, Bermel W, Davey NE, Wagner G, Arthanari H.

Proc Natl Acad Sci U S A. 2018 Feb 20;115(8):E1710-E1719. doi: 10.1073/pnas.1717560115. Epub 2018 Feb 5.

4.

Recent developments in solution nuclear magnetic resonance (NMR)-based molecular biology.

Ziarek JJ, Baptista D, Wagner G.

J Mol Med (Berl). 2018 Jan;96(1):1-8. doi: 10.1007/s00109-017-1560-2. Epub 2017 Jun 23. Review.

5.

Structural basis for chemokine recognition by a G protein-coupled receptor and implications for receptor activation.

Ziarek JJ, Kleist AB, London N, Raveh B, Montpas N, Bonneterre J, St-Onge G, DiCosmo-Ponticello CJ, Koplinski CA, Roy I, Stephens B, Thelen S, Veldkamp CT, Coffman FD, Cohen MC, Dwinell MB, Thelen M, Peterson FC, Heveker N, Volkman BF.

Sci Signal. 2017 Mar 21;10(471). pii: eaah5756. doi: 10.1126/scisignal.aah5756.

6.

New paradigms in chemokine receptor signal transduction: Moving beyond the two-site model.

Kleist AB, Getschman AE, Ziarek JJ, Nevins AM, Gauthier PA, Chevigné A, Szpakowska M, Volkman BF.

Biochem Pharmacol. 2016 Aug 15;114:53-68. doi: 10.1016/j.bcp.2016.04.007. Epub 2016 Apr 19. Review.

7.

Structural analysis of a novel small molecule ligand bound to the CXCL12 chemokine.

Smith EW, Liu Y, Getschman AE, Peterson FC, Ziarek JJ, Li R, Volkman BF, Chen Y.

J Med Chem. 2014 Nov 26;57(22):9693-9. doi: 10.1021/jm501194p. Epub 2014 Nov 13.

8.

Discovery and characterization of a disulfide-locked C(2)-symmetric defensin peptide.

Wommack AJ, Ziarek JJ, Tomaras J, Chileveru HR, Zhang Y, Wagner G, Nolan EM.

J Am Chem Soc. 2014 Oct 1;136(39):13494-7. doi: 10.1021/ja505957w. Epub 2014 Sep 23.

9.

Chemokine cooperativity is caused by competitive glycosaminoglycan binding.

Verkaar F, van Offenbeek J, van der Lee MMC, van Lith LHCJ, Watts AO, Rops ALWMM, Aguilar DC, Ziarek JJ, van der Vlag J, Handel TM, Volkman BF, Proudfoot AEI, Vischer HF, Zaman GJR, Smit MJ.

J Immunol. 2014 Apr 15;192(8):3908-3914. doi: 10.4049/jimmunol.1302159. Epub 2014 Mar 17.

10.

Examining weak protein-protein interactions in start codon recognition via NMR spectroscopy.

Luna RE, Akabayov SR, Ziarek JJ, Wagner G.

FEBS J. 2014 Apr;281(8):1965-73. doi: 10.1111/febs.12667. Epub 2014 Jan 2. Review.

11.

Sulfopeptide probes of the CXCR4/CXCL12 interface reveal oligomer-specific contacts and chemokine allostery.

Ziarek JJ, Getschman AE, Butler SJ, Taleski D, Stephens B, Kufareva I, Handel TM, Payne RJ, Volkman BF.

ACS Chem Biol. 2013 Sep 20;8(9):1955-63. doi: 10.1021/cb400274z. Epub 2013 Jun 26.

12.

Fragment-based optimization of small molecule CXCL12 inhibitors for antagonizing the CXCL12/CXCR4 interaction.

Ziarek JJ, Liu Y, Smith E, Zhang G, Peterson FC, Chen J, Yu Y, Chen Y, Volkman BF, Li R.

Curr Top Med Chem. 2012;12(24):2727-40.

13.

NMR in the Analysis of Functional Chemokine Interactions and Drug Discovery.

Ziarek JJ, Volkman BF.

Drug Discov Today Technol. 2012;9(4):e293-e299.

14.

Heparin oligosaccharides inhibit chemokine (CXC motif) ligand 12 (CXCL12) cardioprotection by binding orthogonal to the dimerization interface, promoting oligomerization, and competing with the chemokine (CXC motif) receptor 4 (CXCR4) N terminus.

Ziarek JJ, Veldkamp CT, Zhang F, Murray NJ, Kartz GA, Liang X, Su J, Baker JE, Linhardt RJ, Volkman BF.

J Biol Chem. 2013 Jan 4;288(1):737-46. doi: 10.1074/jbc.M112.394064. Epub 2012 Nov 12.

15.

A locked, dimeric CXCL12 variant effectively inhibits pulmonary metastasis of CXCR4-expressing melanoma cells due to enhanced serum stability.

Takekoshi T, Ziarek JJ, Volkman BF, Hwang ST.

Mol Cancer Ther. 2012 Nov;11(11):2516-25. doi: 10.1158/1535-7163.MCT-12-0494. Epub 2012 Aug 6.

16.

Structure-based ligand discovery for the protein-protein interface of chemokine receptor CXCR4.

Mysinger MM, Weiss DR, Ziarek JJ, Gravel S, Doak AK, Karpiak J, Heveker N, Shoichet BK, Volkman BF.

Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5517-22. doi: 10.1073/pnas.1120431109. Epub 2012 Mar 19.

17.

Solution structure of CCL21 and identification of a putative CCR7 binding site.

Love M, Sandberg JL, Ziarek JJ, Gerarden KP, Rode RR, Jensen DR, McCaslin DR, Peterson FC, Veldkamp CT.

Biochemistry. 2012 Jan 24;51(3):733-5. doi: 10.1021/bi201601k. Epub 2012 Jan 17.

18.

Monomeric and dimeric CXCL12 inhibit metastasis through distinct CXCR4 interactions and signaling pathways.

Drury LJ, Ziarek JJ, Gravel S, Veldkamp CT, Takekoshi T, Hwang ST, Heveker N, Volkman BF, Dwinell MB.

Proc Natl Acad Sci U S A. 2011 Oct 25;108(43):17655-60. doi: 10.1073/pnas.1101133108. Epub 2011 Oct 11.

19.

The CXC chemokine receptor 4 ligands ubiquitin and stromal cell-derived factor-1α function through distinct receptor interactions.

Saini V, Staren DM, Ziarek JJ, Nashaat ZN, Campbell EM, Volkman BF, Marchese A, Majetschak M.

J Biol Chem. 2011 Sep 23;286(38):33466-77. doi: 10.1074/jbc.M111.233742. Epub 2011 Jul 13.

20.

Sulfotyrosine recognition as marker for druggable sites in the extracellular space.

Ziarek JJ, Heroux MS, Veldkamp CT, Peterson FC, Volkman BF.

Int J Mol Sci. 2011;12(6):3740-56. doi: 10.3390/ijms12063740. Epub 2011 Jun 8.

21.

Binding site identification and structure determination of protein-ligand complexes by NMR a semiautomated approach.

Ziarek JJ, Peterson FC, Lytle BL, Volkman BF.

Methods Enzymol. 2011;493:241-75. doi: 10.1016/B978-0-12-381274-2.00010-8.

22.

Targeting SDF-1/CXCL12 with a ligand that prevents activation of CXCR4 through structure-based drug design.

Veldkamp CT, Ziarek JJ, Peterson FC, Chen Y, Volkman BF.

J Am Chem Soc. 2010 Jun 2;132(21):7242-3. doi: 10.1021/ja1002263.

23.

Monomeric structure of the cardioprotective chemokine SDF-1/CXCL12.

Veldkamp CT, Ziarek JJ, Su J, Basnet H, Lennertz R, Weiner JJ, Peterson FC, Baker JE, Volkman BF.

Protein Sci. 2009 Jul;18(7):1359-69. doi: 10.1002/pro.167.

Supplemental Content

Loading ...
Support Center